Literature DB >> 21676337

Role of LRRK2 kinase dysfunction in Parkinson disease.

Azad Kumar1, Mark R Cookson.   

Abstract

Parkinson disease is a common and usually sporadic neurodegenerative disorder. However, a subset of cases are inherited and, of these, mutations in the gene encoding leucine-rich repeat kinase 2 (LRRK2) are the most frequent genetic cause of disease. Here, we will discuss recent progress in understanding how LRRK2 mutations lead to disease and how this might have therapeutic implications. The effect of mutations on LRRK2 enzyme function provides clues as to which functions of the protein are important to disease. Recent work has focused on the kinase and GTP-binding domains of LRRK2, and it is assumed that these will be therapeutically important, although there is a substantial amount of work to be done to address this hypothesis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21676337      PMCID: PMC4672634          DOI: 10.1017/S146239941100192X

Source DB:  PubMed          Journal:  Expert Rev Mol Med        ISSN: 1462-3994            Impact factor:   5.600


  99 in total

1.  Insight into the mode of action of the LRRK2 Y1699C pathogenic mutant.

Authors:  Veronique Daniëls; Renée Vancraenenbroeck; Bernard M H Law; Elisa Greggio; Evy Lobbestael; Fangye Gao; Marc De Maeyer; Mark R Cookson; Kirsten Harvey; Veerle Baekelandt; Jean-Marc Taymans
Journal:  J Neurochem       Date:  2011-01       Impact factor: 5.372

2.  Escaping Parkinson's disease: a neurologically healthy octogenarian with the LRRK2 G2019S mutation.

Authors:  Denise M Kay; Patricia Kramer; Don Higgins; Cyrus P Zabetian; Haydeh Payami
Journal:  Mov Disord       Date:  2005-08       Impact factor: 10.338

3.  Expression, purification and preliminary biochemical studies of the N-terminal domain of leucine-rich repeat kinase 2.

Authors:  Bin Lu; Yujia Zhai; Chan Wu; Xiaoyun Pang; Zhiheng Xu; Fei Sun
Journal:  Biochim Biophys Acta       Date:  2010-05-20

4.  Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S.

Authors:  Xianting Li; Jyoti C Patel; Jing Wang; Marat V Avshalumov; Charles Nicholson; Joseph D Buxbaum; Gregory A Elder; Margaret E Rice; Zhenyu Yue
Journal:  J Neurosci       Date:  2010-02-03       Impact factor: 6.167

5.  Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase.

Authors:  Junpeng Deng; Patrick A Lewis; Elisa Greggio; Eli Sluch; Alexandra Beilina; Mark R Cookson
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-29       Impact factor: 11.205

Review 6.  The Roco protein family: a functional perspective.

Authors:  Ignacio Marín; Wouter N van Egmond; Peter J M van Haastert
Journal:  FASEB J       Date:  2008-06-03       Impact factor: 5.191

7.  Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease.

Authors:  Yanping Li; Wencheng Liu; Tinmarla F Oo; Lei Wang; Yi Tang; Vernice Jackson-Lewis; Chun Zhou; Kindiya Geghman; Mikhail Bogdanov; Serge Przedborski; M Flint Beal; Robert E Burke; Chenjian Li
Journal:  Nat Neurosci       Date:  2009-06-07       Impact factor: 24.884

8.  Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease.

Authors:  Byoung Dae Lee; Joo-Ho Shin; Jackalina VanKampen; Leonard Petrucelli; Andrew B West; Han Seok Ko; Yun-Il Lee; Kathleen A Maguire-Zeiss; William J Bowers; Howard J Federoff; Valina L Dawson; Ted M Dawson
Journal:  Nat Med       Date:  2010-08-22       Impact factor: 53.440

9.  Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2.

Authors:  Xianming Deng; Nicolas Dzamko; Alan Prescott; Paul Davies; Qingsong Liu; Qingkai Yang; Jiing-Dwan Lee; Matthew P Patricelli; Tyzoon K Nomanbhoy; Dario R Alessi; Nathanael S Gray
Journal:  Nat Chem Biol       Date:  2011-03-06       Impact factor: 15.040

Review 10.  Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions.

Authors:  Elisa Greggio; Mark R Cookson
Journal:  ASN Neuro       Date:  2009-04-14       Impact factor: 4.146

View more
  13 in total

1.  Inhibitors of LRRK2 as Treatment for Parkinson's Disease: Patent Highlight.

Authors:  Ahmed F Abdel-Magid
Journal:  ACS Med Chem Lett       Date:  2012-07-27       Impact factor: 4.345

Review 2.  LRRK2, a puzzling protein: insights into Parkinson's disease pathogenesis.

Authors:  A Raquel Esteves; Russell H Swerdlow; Sandra M Cardoso
Journal:  Exp Neurol       Date:  2014-06-04       Impact factor: 5.330

Review 3.  Parkinson's disease: convergence on synaptic homeostasis.

Authors:  Sandra-Fausia Soukup; Roeland Vanhauwaert; Patrik Verstreken
Journal:  EMBO J       Date:  2018-07-31       Impact factor: 11.598

Review 4.  Kinase inhibitors: the road ahead.

Authors:  Fleur M Ferguson; Nathanael S Gray
Journal:  Nat Rev Drug Discov       Date:  2018-03-16       Impact factor: 84.694

Review 5.  Animal models of Parkinson's disease: a gateway to therapeutics?

Authors:  Weidong Le; Pavani Sayana; Joseph Jankovic
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

Review 6.  Parkinson's disease.

Authors:  Timothy R Mhyre; James T Boyd; Robert W Hamill; Kathleen A Maguire-Zeiss
Journal:  Subcell Biochem       Date:  2012

7.  Characterization of TAE684 as a potent LRRK2 kinase inhibitor.

Authors:  Jinwei Zhang; Xianming Deng; Hwan Geun Choi; Dario R Alessi; Nathanael S Gray
Journal:  Bioorg Med Chem Lett       Date:  2012-01-28       Impact factor: 2.823

8.  Discovery of a Pyrrolopyrimidine (JH-II-127), a Highly Potent, Selective, and Brain Penetrant LRRK2 Inhibitor.

Authors:  John M Hatcher; Jinwei Zhang; Hwan Geun Choi; Genta Ito; Dario R Alessi; Nathanael S Gray
Journal:  ACS Med Chem Lett       Date:  2015-04-07       Impact factor: 4.345

9.  GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor.

Authors:  Alastair D Reith; Paul Bamborough; Karamjit Jandu; Daniele Andreotti; Lucy Mensah; Pamela Dossang; Hwan Geun Choi; Xianming Deng; Jinwei Zhang; Dario R Alessi; Nathanael S Gray
Journal:  Bioorg Med Chem Lett       Date:  2012-07-07       Impact factor: 2.823

10.  Brain Penetrant LRRK2 Inhibitor.

Authors:  Hwan Geun Choi; Jinwei Zhang; Xianming Deng; John M Hatcher; Matthew P Patricelli; Zheng Zhao; Dario R Alessi; Nathanael S Gray
Journal:  ACS Med Chem Lett       Date:  2012-06-18       Impact factor: 4.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.